Article Details
Retrieved on: 2025-04-09 16:16:46
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Merida is not the only biotech setting its sights on the Graves' disease market. Immunovant is developing batoclimab, a monoclonal antibody currently ...
Article found on: www.pharmaceutical-technology.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here